No Data
89bio to Participate in the BofA Securities 2024 Health Care Conference
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
Calendar of U.S. Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH
PDF Version Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ETSAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ET
89bio Coverage Assumed by B of A Securities at Buy
89bio Coverage Assumed by B of A Securities at Buy
Express News | B of A Securities Assumes 89bio at Buy, Announces Price Target of $30